Menu
Search
|

Menu

Close
X

Mersana Therapeutics Inc MRSN.OQ (NASDAQ Stock Exchange Global Select Market)

15.36 USD
+0.20 (+1.32%)
As of Feb 16
chart
Previous Close 15.16
Open 15.17
Volume 20,016
3m Avg Volume 20,690
Today’s High 15.64
Today’s Low 15.06
52 Week High 21.01
52 Week Low 12.65
Shares Outstanding (mil) 22.71
Market Capitalization (mil) 429.84
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY17
14
FY16
25
EPS (USD)
FY17
-1.090
FY16
-0.605
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
--
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

David Mott
Chairman of the Board, Since 2013
Salary: --
Bonus: --
Anna Protopapas
President, Chief Executive Officer, Director, Since 2016
Salary: --
Bonus: --
Timothy Lowinger
Chief Scientific Officer, Since
Salary: --
Bonus: --
Wayne Foster
Vice President - Finance, Since
Salary: --
Bonus: --
Donald Bergstrom
Chief Medical Officer, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

840 Memorial Dr
CAMBRIDGE   MA   02139-3789

Phone: +1617.4980020

Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.

SPONSORED STORIES